Development of peptide vaccine using nano-particle adjuvant for naturally occuring tumors in dogs

使用纳米颗粒佐剂开发针对狗天然肿瘤的肽疫苗

• 批准号: 23580443
• 负责人: MOMOI YASUYUKI
• 金额: $ 3.58万
• 依托单位: Kagoshima University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23580443/
• 关键词: 犬; 癌; 腫瘍; ワクチン; 癌ワクチン; アジュバント; リンパ腫

TThe aim of this study is to establish new tumor vaccine for canine naturally occurring tumor. We synthesized peptides in reference to epitope of tumor specific antigens. The peptides were conjugated with keyhole limpet hemocyanin and absorbed to the surface of nano-particle (adjuvant). The resultant products successfully induced antibody production against the peptide, however, cellular immunity against the target cells was not detected. Adverse events were not observed in vaccinated dogs but the clinical benefit (objective tumor reduction) was not detected in a dog with lymphoma. We newly reported canine TRP-2 cDNA nucleotide sequence and constructed TRP-2, melan-A, CD20-GFP fusion molecule, mammalian expression plasmid. The findings obtained in this study may be helpful to establish canine tumor vaccine.

本研究旨在为犬自然发生的肿瘤建立新的肿瘤疫苗。我们根据肿瘤特异性抗原的表位合成了多肽。将肽与锁孔帽贝血青素偶联，吸附到纳米颗粒（佐剂）表面。所得产物成功地诱导了针对肽的抗体产生，然而，未检测到针对靶细胞的细胞免疫。在接种疫苗的犬中未观察到不良事件，但在淋巴瘤犬中未检测到临床获益（客观肿瘤减少）。新报道了犬TRP-2 cDNA核苷酸序列，构建了TRP-2、melan-A、CD20-GFP融合分子和哺乳动物表达质粒。本研究结果对建立犬肿瘤疫苗有一定的参考价值。

项目成果

本研究の報告は鹿児島大学リポジトリに登 録し閲覧可能である。

这项研究的报告可以在鹿儿岛大学知识库中注册和查看。

犬の肥満細胞腫におけるKITの発現

KIT在犬肥大细胞肿瘤中的表达

• 发表时间: 2013
• 作者: 賓田亜以;三浦直樹;桃井康行
• 通讯作者: 桃井康行

研究内容

研究内容